Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Elamipretide, a Mitochondria-Targeted Drug for the Treatment of Vision Loss
Scott W. Cousins, MD
Updates from the Field
2019
Episode 1: Review of the Clarity Study with Dr. Amin Kherani
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017
Microvascular Changes in the Choriocapillaris of Diabetic Patients Without Retinopathy Investigated by Swept-Source OCT Angiography
Kasra Rezaei, M.D.
On Demand Cases, Courses, and Papers
2020

Category: Diabetic Retinopathy

See more